Noguchi S, Miyauchi K, Nishizawa Y, Koyama H
Department of Surgery, Center for Adult Diseases, Osaka, Japan.
Cancer. 1988 Apr 1;61(7):1345-9. doi: 10.1002/1097-0142(19880401)61:7<1345::aid-cncr2820610712>3.0.co;2-j.
The behavior of progesterone receptor (PR) values over time in human breast cancer during tamoxifen treatment was studied. Of 97 patients with operable breast cancer, 24 were preoperatively treated with tamoxifen (20 mg twice daily) for 3 days (TAM 3-day), 22 were treated for 7 days (TAM 7-day), 21 for 14 days (TAM 14-day), and 30 received no treatment (control group). Surgically removed breast tumors were assayed for the progesterone receptor by the dextran-coated charcoal method. The PR values (fmol/mg DNA) (mean +/- standard error [SE]) of PR-positive tumors in the control, TAM-3, TAM-7, and TAM-14 day groups were 571 +/- 176, 1699 +/- 408 (P less than 0.01), 1675 +/- 463 (P less than 0.05), and 686 +/- 191, respectively. There was a 4.6-fold increase in the mean PR value in postmenopausal patients and a two-fold increase in premenopausal patients after TAM treatment for 3 and 7 days. We concluded that PR induction provoked by TAM reached a peak on day 3, continuing at this level until day 7. A longer treatment (14 days) with TAM appears to abolish the PR inducing activity, probably because of, first, estrogenic and, later, the antiestrogenic effects of TAM.
研究了他莫昔芬治疗期间人乳腺癌中孕激素受体（PR）值随时间的变化情况。97例可手术乳腺癌患者中，24例术前接受他莫昔芬（每日2次，每次20 mg）治疗3天（他莫昔芬3天组），22例治疗7天（他莫昔芬7天组），21例治疗14天（他莫昔芬14天组），30例未接受治疗（对照组）。采用葡聚糖包被活性炭法对手术切除的乳腺肿瘤进行孕激素受体检测。对照组、他莫昔芬3天组、他莫昔芬7天组和他莫昔芬14天组PR阳性肿瘤的PR值（fmol/mg DNA）（均值±标准误[SE]）分别为571±176、1699±408（P<0.01）、1675±463（P<0.05）和686±191。他莫昔芬治疗3天和7天后，绝经后患者的平均PR值增加4.6倍，绝经前患者增加2倍。我们得出结论，他莫昔芬诱导的PR在第3天达到峰值，并维持该水平至第7天。他莫昔芬更长时间（14天）的治疗似乎消除了PR诱导活性，可能首先是由于他莫昔芬的雌激素作用，随后是抗雌激素作用。
